Surgery, radiation and chemotherapy just don’t cut it against glioblastoma, with 5-year survival rates as low as 5%. In new research, authors show that CAR-T cells targeting CSPG4 effectively treats glioblastoma in mouse models, with no evidence of antigen loss or tumor escape.

See the source article by following the link below:
Surgery, radiation and chemotherapy just don’t cut it against glioblastoma, with 5-year survival rates as low as 5%. In new research, authors show that CAR-T cells targeting CSPG4 effectively treats glioblastoma in mouse models, with no evidence of antigen loss or tumor escape.